Teva Pharmaceutical Industries (TEVA)

Executive Summary

Teva Pharmaceutical Industries is a global leader in generic and specialty pharmaceuticals, with a strong presence in CNS, respiratory, and oncology. The company operates an integrated value chain from API manufacturing to finished dosage forms, supplying millions of patients daily. Despite facing headwinds from generic competition and high debt, Teva's diverse portfolio and pipeline of nine drug candidates position it for recovery. Key products include Ajovy (migraine) and a broad generics lineup. The company's strategic focus on biosimilars and complex generics is expected to drive growth, supported by a large global manufacturing network.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of biosimilar for Stelara (ustekinumab)75% success
• Q4 2026Launch of generic Advair Diskus (fluticasone/salmeterol)80% success
• Q1 2027Phase 3 data readout for TEV-749 in Huntington's disease40% success